FourThought Financial’s Jazz Pharmaceuticals JAZZ Stock Holding History

FourThought Financial’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$9K	Sell	66 -5	-7%	-$760	﹤0.01%	1059
2022 Q2	$11K	Sell	71 -27	-28%	-$4.16K	﹤0.01%	998
2022 Q1	$15K	Sell	98 -28	-22%	-$4.06K	﹤0.01%	971
2021 Q4	$16K	Sell	126 -2	-2%	-$263	﹤0.01%	971
2021 Q3	$16K	Sell	128 -17	-12%	-$2.57K	﹤0.01%	1001
2021 Q2	$25K	Sell	145 -6	-4%	-$1.04K	﹤0.01%	896
2021 Q1	$24K	Sell	151 -30	-17%	-$4.94K	﹤0.01%	861
2020 Q4	$29K	Buy	+181	New	+$27K	﹤0.01%	790

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FourThought Financial's JAZZ Position: Q3 2022 in Review

FourThought Financial reduced its Jazz Pharmaceuticals (JAZZ) stake by 7% in Q3 2022, selling an estimated $760 and leaving 66 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #1059.

FourThought Financial first reported a position in JAZZ in Q4 2020 and has held it in 8 quarters since. The position peaked at $29K in Q4 2020. 468 funds tracked by Wall St. Rank hold JAZZ as of Q3 2022.

FourThought Financial held 66 shares of Jazz Pharmaceuticals worth $9K as of Q3 2022.
FourThought Financial sold 5 Jazz Pharmaceuticals shares in Q3 2022, an estimated $760.
Jazz Pharmaceuticals made up ﹤0.01% of FourThought Financial's portfolio in Q3 2022, its #1059 holding.
FourThought Financial first reported a position in Jazz Pharmaceuticals in Q4 2020 and has held it in 8 quarters since.
FourThought Financial's Jazz Pharmaceuticals position peaked at $29K in Q4 2020.
468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.